NASDAQ · Biotechnology

ALDX (ALDX) Stock

$1.60 +3.23% NASDAQ: ALDX Healthcare

Valuation

MetricValue
Price$1.60
Market Cap$96.51M
P/E Ratio-2.77
P/B Ratio2.12
P/S Ratio0.00
EPS (TTM)$-0.56
52-Week High$6.17
52-Week Low$1.07
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-77.27%
ROA-47.22%
ROCE-79.55%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.37
Current Ratio2.57

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-56.0M$-63.0M$-43.0M$-60.0M$-35.0M
Net Profit$-58.0M$-62.0M$-38.0M$-56.0M$-34.0M
EPS$-1.07$-1.06$-0.64$-0.94$-0.56
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$233.0M$181.0M$148.0M$105.0M$72.0M
Total Liabilities$27.0M$30.0M$29.0M$34.0M$28.0M
Cash$230.0M$144.0M$143.0M$55.0M$70.0M
Borrowings$16.0M$16.0M$16.0M$15.0M$16.0M

Latest News

Levicept Appoints Darlene Deptula-Hicks as CFO GlobeNewswire · Jul 7, 2026 CEO, President & Director of Aldeyra Therapeutics Picks Up 18% More Stock Simply Wall St. · Jun 10, 2026 Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors Business Wire · Jun 10, 2026 Aldeyra Therapeutics Insider Bought Shares Worth $418,450, According to a Recent SEC Filing MT Newswires · Jun 5, 2026 Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment MarketBeat · Jun 5, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-43.0M$-57.0M$-30.0M$-43.0M$-33.35T
Investing Cash Flow$0$-30.0M$30.0M$-45.0M$47.74T
Financing Cash Flow$5.0M$0$-1.0M$0$1.12T
Net Cash Flow$152.0M$-85.0M$-2.0M$-88.0M$15.51T
Free Cash Flow$-43.0M$-57.0M$-30.0M$-43.0M$-33.35T

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-27.79%
Quick Ratio2.72
Interest Coverage-17.50
Return 1Y-61.48%
Return 3Y-75.38%
Return 5Y-80.08%

Ownership

Insiders Held3.60%
Institutions Held62.79%
Institutions Float Held65.14%
Institutional HolderSharesReport Date
Knoll Capital Management, LLC5,475,5162026-03-31
Blackrock Inc.3,763,8872026-03-31
AQR Capital Management, LLC2,829,8752026-03-31
Vanguard Capital Management LLC2,363,7422026-03-31
Kingdon Capital Management LLC2,152,3152026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACIU $2.31 +0.22% -4.04 $234.59M 0.00%
AMRNAmarin Corporation plc $14.58 +0.80% -9.00 $301.45M 0.00%
ANRO $28.67 +0.70% -6.29 $1.01B 0.00%
CADL $10.59 +0.09% -11.10 $775.93M 0.00%
CLLSCellectis S.A. $2.81 -2.26% -4.14 $282.17M 0.00%

About ALDX

ALDX is led by CEO Todd C. Brady, publicly traded since 2014.

ALDX stock trades at $1.60 with a market capitalization of $96.51M. The stock is valued at a price-to-earnings (P/E) ratio of -2.77, price-to-book of 2.12, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.07 and $6.17, and currently trades 74.1% below its 52-week high.

On profitability, ALDX generates a return on equity (ROE) of -77.27%, return on capital employed of -79.55%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides